Immunogenicity of anti-TNF antibodies. Has the veil been lifted?

Gut

Volumn 60, Issue 3, 2011, Pages 285-286

  Van Assche, Gert ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; CERTOLIZUMAB PEGOL; ERYTHROPOIETIN; GAMMA INTERFERON; IMMUNOGLOBULIN F(AB) FRAGMENT; INFLIXIMAB; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

CLINICAL PRACTICE; CROHN DISEASE; ENTERITIS; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; IMMUNE SYSTEM; IMMUNOGENICITY; NOTE; PRIORITY JOURNAL; PROTEIN ENGINEERING; RECEIVER OPERATING CHARACTERISTIC; TREATMENT RESPONSE;

ANTIBODIES, ANTI-IDIOTYPIC; ANTIBODIES, MONOCLONAL; GASTROINTESTINAL AGENTS; HUMANS; INFLAMMATORY BOWEL DISEASES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 79851509084     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gut.2009.199687     Document Type: Note

References (14)

1. Hwang WYK, Foote J. Immunogenicity of engineered antibodies. Methods 2005;36:3-10. (Pubitemid 40558811)
2. Locatelli F, Aljama P, Barany P, et al. Erythropoiesis stimulating agents and antibody mediated pure red cell aplasia. Nephrol Dial Transplant 2004;19:288-93.
3. Polman C, Kappos L, White R, et al. Neutralizing antibodies during treatment of secondary progressive MS with interferon-beta-1b. Neurology 2003;60:37-43. (Pubitemid 36070641)
4. Baert F, Noman M, Vermeire S, et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med 2003;348:601-8. (Pubitemid 36204954)
5. Farrell RJ, Alsahli M, Jeen YT, et al. Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn's disease: a randomized controlled trial. Gastroenterology 2003;124:917-24. (Pubitemid 36389794)
6. Hanauer SB, Wagner CL, Bala M. Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease. Clin Gastroenterol Hepatol 2004;2:542-53. (Pubitemid 38834038)
7. Maser EA, Villela R, Silverberg MS, et al. Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn's disease. Clin Gastroenterol Hepatol 2006;4:1248-54. (Pubitemid 44512213)
8. Vermeire S, Noman M, Van Assche G, et al. Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease. Gut 2007;56:1226-31. (Pubitemid 47300423)
9. Karmiris K, Paintaud G, Noman M, et al. Influence of trough serum levels and immunogenicity on long-term outcome of adalimumab therapy in Crohn's disease. Gastroenterology 2009;137:1628-40.
10. Bartelds GM, Wijbrandts CA, Nurmohamed MT, et al. Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis. Ann Rheum Dis 2007;66:921-6. (Pubitemid 46999794)
11. Ben-Horin S, Yavzori M, Katz L, et al. The immunogenic part of infliximab is the F(ab′)2, but measuring antibodies to the intact infliximab molecule is more clinically useful. Gut 2011;66:41-8.
12. St Clair EW, Wagner CL, Fasanmade AA, et al. The relationship of serum infliximab concentrations to clinical improvement in rheumatoid arthritis: results from ATTRACT, a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2002;46:1451-9. (Pubitemid 34620190)
13. Svenson M, Geborek P, Saxne T, et al. Monitoring patients treated with anti-TNF-α biopharmaceuticals: assessing serum infliximab and anti-infliximab antibodies. Rheumatology 2007;46:1828-34. (Pubitemid 350168300)
14. Afif W, Loftus EVJr, Faubion WA, et al. Clinical utility of measuring infliximab and human anti-chimeric antibody concentrations in patients with inflammatory bowel disease. Am J Gastroenterol 2010;105:1133-9.